¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glass factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • human antihemophilic factor
    »ç¶÷Ç×Ç÷¿ìº´ÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • initiation factor
    ½ÃÀÛÀÎÀÚ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • ketogenic factor
    ÄÉÅæ»ý¼ºÀÎÀÚ
  • labile factor
    1. ºÒ¾ÈÁ¤ÀÎÀÚ 2. ºÒ¾ÈÁ¤¿ä¼Ò
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • leukotaxic factor
    ¹éÇ÷±¸½ò¸²ÀÎÀÚ
  • luteinizing hormone releasing factor
    Ȳ(»ö)üÇü¼ºÈ£¸£¸óºÐºñÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    Ȳ(»ö)üÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lactogenic factor
    Á¥ÃËÁøÀÎÀÚ
  • lymphocytosis stimulating factor
    ¸²ÇÁ±¸Áõ°¡ÀÚ±ØÀÎÀÚ
  • migration inhibition factor
    À̵¿ÀúÁöÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • lymphocytosis stimulating factor
    ¸²ÇÁ±¸Áõ°¡ÀÚ±ØÀÎÀÚ
  • macrophage aggregating factor
    Å«Æ÷½Ä¼¼Æ÷ÀÀÁýÀÎÀÚ
  • macrophage arming factor
    Å«Æ÷½Ä¼¼Æ÷¹«ÀåÀÎÀÚ
  • macrophage chemotactic factor
    Å«Æ÷½Ä¼¼Æ÷È­ÇÐÁÖ¼ºÀÎÀÚ, Å«Æ÷½Ä¼¼Æ÷È­Çнò¸²ÀÎÀÚ
  • macrophage colony-stimulating factor
    Å«Æ÷½Ä¼¼Æ÷Áý¶ôÀÚ±ØÀÎÀÚ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • macrophage-activating factor
    Å«Æ÷½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • migration inhibition factor
    Æ÷½Ä¼¼Æ÷À̵¿ÀúÇØÀÎÀÚ
  • mitogenic factor
    ºÐ¿­ÃËÁøÀÎÀÚ
  • myocardial depressant factor
    ½ÉÀå±Ù¾ïÁ¦ÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • neutron kerma factor
    Áß¼ºÀÚÄ¿¸¶°è¼ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • anisotropy factor
    ºñµî¹æ¼º°è¼ö
  • antigen, colonization factor
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
  • antihemophilic A factor =AHA
    Ç×Ç÷¿ìº´ AÀÎÀÚ(?ËöËö).
  • antihemophilic factor =AHF
    Ç×Ç÷¿ìº´ÀÎÀÚ(¡­ì×í­)
  • antihemophilic factor =AHF
    Ç×Ç÷¿ìº´ÀÎÀÚ(?ËöËö).
  • antihemophllic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antiinsulin factor
    Ç×Àν¶¸°ÀÎÀÚ.
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ(ù÷ãêÌèæúì×í­).
  • antinuclear factor =ANF
    Ç×ÇÙÀÎÀÚ.
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ.
  • antiphagocytic factor
    Ç׎½ÄÀÎÀÚ, Ç׽ıÕÀÎÀÚ
  • antirachitic factor
    Ç×±¸·çº´ÀÎÀÚ(¡­ì×í­).
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ.
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ(ù÷ÝÕìôì×í­).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • chemotactic factor
    (È­ÇÐ)ÁÖÈ­ÀÎÀÚ, È­ÇÐÁÖ¼ºÀÎÀÚ(¡­ì×í­)
  • cholestatic factor
    (Ãé)´äÁó¿ïüÀÎÀÚ.
  • circumstance factor
    »óȲÀÎÀÚ(íîüÏì×í­).
  • citrovorum factor
    ½ÃÆ®·Îº¸·ë <ÀÎÀÚ>
  • clotting factor
    ÀÀ°íÀÎÀÚ, ÀÀÇ÷ÀÎÀÚ(¡­ì×í­)
  • clotting factor
    ÀÀ°íÀÎÀÚ, ÀÀÇ÷ÀÎÀÚ(?ËöËö).
  • clumping factor
    ÀÀ±«ÀÎÀÚ
  • coagulase-reacting factor
    Ç÷ÀåÀÀ°íÈ¿¼Ò ¹ÝÀÀÀÎÀÚ, ÄھƱֶóÁ¦ ¹ÝÀÀÀÎÀÚ
  • coagulation factor
    ÀÀ°íÀÎÀÚ(ëêͳì×í­)
  • coagulation factor
    ÀÀ°íÀÎÀÚ(¡­ì×í­).
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor deficiency
    ÀÀ°íÀÎÀÚ°áÇÌ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ ¾ïÁ¦Á¦<¾ïÁ¦ ¹°Áú
  • colonization factor
    Áý¶ôÇü¼ºÀÎÀÚ, ¼¼Æ÷±ºÇü¼ºÀÎÀÚ
  • colonizing factor antigen (CFA)
    Áý¶ôÇü¼ºÀÎÀÚÇ׿ø, ¼¼Æ÷±ºÇü¼ºÀÎÀÚÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • factor X
    ÀÎÀÚ(ì×í­) X
  • factor Y
    ÀÎÀÚ(ì×í­) Y
  • fertility factor
    ¼öÁ¤ ÀÎÀÚ (áôïñì×í­)
  • F factor
    F ÀÎÀÚ(ì×í­)
  • F' factor
    F' ÀÎÀÚ(ì×í­)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
  • Fitzgerald factor
    ÇÍÁ¦¶öµå ÀÎÀÚ(ì×í­)
  • g factor
    g ÀÎÀÚ(ì×í­)
  • G factor
    G ÀÎÀÚ(ì×í­)
  • glucose tolerance factor
    ±Û·çÄÚ½º ³»¼º ÀÎÀÚ(Ò±àõì×í­)
  • growth factor
    ¼ºÀåÀÎÀÚ (à÷íþì×í­)
  • Hageman factor
    ÇØ±×¸Õ ÀÎÀÚ (ì×í­)
  • heat labile citrovorum factor
    ¿­ºÒ¾ÈÁ¤(æðÝÕäÌïÒ) ½ÃÆ®·Î¹ö·³ ÀÎÀÚ(ì×í­)
  • helper factor
    µµ¿òÀÌ ÀÎÀÚ(ì×í­)
  • hydration factor
    ¼öÈ­ ÀÎÀÚ(â©ûùì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
LIF laser-induced fluorescence; left iliac fossa; left index finger; leukemia-inhibiting factor; leukocy...
MF magnetic field; meat free; medium frequency; megafarad; membrane filler; merthiolate-formaldehyde [s...
MSF macrophage slowing factor; macrophage spreading factor; Medicins sans Frontieres [Doctors without Bo...
PIF paratoid isoelectric focusing variant protein; peak inspiratory flow; proinsulin-free; prolactin-inh...
SPF skin protection factor; specific-pathogen free; spectrophotofluorometer; S-phase fraction; split pro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
NGF 125)I-nerve growth factor
(125I)-EGF 125I)-labeled epidermal growth factor
125-I-EGF 125I-labelled epidermal growth factor
CBF 2/core binding factor
CSF Colony Stimulating Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • endothelium-derived relaxing factor
    ³»ÇÇ ¼¼Æ÷¼º ÀÌ¿Ï ÀÎÀÚ
  • endurance factor
    Áö¼Ó ÀÎÀÚ
  • environmental chemotactic factor
    ȯ°æ¼º È­ÇÐ ÁÖ¼º ÀÎÀÚ
  • eosinophil chemotactic factor
    È£»ê±¸ È­ÇÐ ÁÖ¼º ÀÎÀÚ
  • excess factor
    °úÀ× ÀÎÀÚ
  • F factor
    ¿¡ÇÁ ÀÎÀÚ
    ´ëÀå±Õ¿¡¼­ ¿õ¼ºÀ» ºÎ¿©ÇÏ´Â ÀÛ¿ëÀ» °¡Áø ¿¡ÇǼؼº ÀÎÀÚ. ÀÌ ÀÎÀÚ°¡ ÀÖ´Â ¼¼±ÕÀ» F¶ó ÇÏ¸ç ¿õ¼ºÀ» ³ªÅ¸³»°í, À̰ÍÀÌ ¾ø´Â °ÍÀ» F¶ó°í ÇÏ¿© ÀÚ¼ºÀ» ³ªÅ¸³½´Ù. µÎ ¼¼Æ÷¸¦ È¥ÇÕ ¹è¾çÇϸé Á¢ÇÕÀÌ ÀϾ F ¼¼Æ÷ÀÇ F ÀÎÀÚ´Â F ¼¼Æ÷·Î µé¾î°¡ ÀÚ¼ºÀ» ¿õ¼ºÀ¸·Î ¹Ù²Û´Ù. F ÀÎÀÚ¿¡ ¼¼±Õ ¿°»öüÀÇ ÀϺκÐÀÌ ºÎÂøµÇ¾î ÀÖ´Â »óŸ¦ F'¶ó Çϰí, F ÀÎÀÚ°¡ ¼¼±Õ ¿°»öü ¼ÓÀ¸·Î µé¾î°£ »óÅÂÀÇ °ÍÀ» Hfr
  • factor
    ÀÎÀÚ
    °á°ú »êÃâ¿¡ ÇÊ¿äÇÑ ÀÛ¿ëÀ̳ª ¹°Áú. ¿¹ÄÁ´ë ÀÀ°í ÀÎÀÚ. º¸Åë ÀÛ¿ë ±âÀüÀ̳ª È­ÇÐÀû ¼ºÁúÀÌ ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀº ¹°ÁúÀ» °¡¸£Å°´Âµ¥ ¾²ÀÌ´Â ¿ë¾î·Î ³»ºÐºñ ¿µ¿ª¿¡¼­´Â ±× ÀÎÀÚÀÇ È­ÇÐÀû ¼ºÁúÀÌ ±Ô¸íµÈ ÈÄ¿¡´Â 'È£¸£¸ó'À̶ó°í °³ÄªÇÑ´Ù.
  • factor deficiency
    ÀÎÀÚ °áÇÌ, Á¦ÀÎÀÚ °áÇÌÁõ
  • factor IX deficiency
    Á¦ 9ÀÎÀÚ °áÇÌÁõ, Á¦9ÀÎÀÚ °áÇÌ
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
  • factor VII deficiency
    Á¦ 7ÀÎÀÚ °áÇÌÁõ
  • factor VIII deficiency
    Á¦ 8ÀÎÀÚ °áÇÌ
  • factor XI deficiency
    Á¦11ÀÎÀÚ °áÇÌ
    ÀÌ ÀÎÀÚ°¡ ºÎÁ·µÇ¸é Ç÷¿ìº´ C³ª Rosenthal ÁõÈıºÀ¸·Î ºÒ¸®´Â Àü½Å¼º Ç÷¾× ÀÀ°í Àå¾Ö¸¦ ÀÏÀ¸Å°´Âµ¥ °íÀüÀû Ç÷¿ìº´°ú À¯»çÇÏ´Ù.
  • follicle stimulating hormone releasing factor
    ³­Æ÷ ÀÚ±Ø È£¸£¸ó ¹æÃâ ÀÎÀÚ
  • Hageman factor
    ÇϰԸ¸ ÀÎÀÚ
    factor ?.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
radiation weighting factor In radiation protection, a factor weighting the absorbed dose of radiation of a specific type and energy for its effect on tissue.
See: equivalent dose.
(05 Mar 2000)
maise factor <molecular biology, plant biology> A naturally occurring cytokinin, originally isolated from maize seeds. Its riboside is also a cytokinin.
(18 Nov 1997)
vascular endothelial growth factor A growth factor that is responsible for the growth of blood vessels.
(12 Dec 1998)
mammotropic factor <protein> Pituitary lactogenic hormone (23 kD) Synthesised on endoplasmic reticulum bound ribosomes as preprolactin that has an N terminal signal peptide that is cleaved from the mature form. The conversion of preprolactin to prolactin has been much used as an assay for membrane insertion.
(18 Nov 1997)
receptors, atrial natriuretic factor Cell surface proteins that bind atrial natriuretic factor with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, colony-stimulating factor Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells.
(12 Dec 1998)
receptors, epidermal growth factor-urogastrone Glycoproteins of about 170 kD that have protein kinase activity and span the plasma membranes of growing cells, including tumours. They are activated by the binding of epidermal growth factor-urogastrone which then initiates DNA and protein synthesis. They are not found on mitotically quiescent cells except in the stomach where they control the synthesis and release of digestive enzymes and gastric acid. Transforming growth factor alpha also binds to and activates these receptors.
(12 Dec 1998)
receptors, fibroblast growth factor Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.
(12 Dec 1998)
receptors, granulocyte-colony-stimulating factor Receptors that bind and internalise granulocyte-colony-stimulating factor. Their mw is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells.
(12 Dec 1998)
receptors, granulocyte-macrophage colony-stimulating factor Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor.
(12 Dec 1998)
receptors, growth factor Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.
(12 Dec 1998)
receptors, insulin-like-growth factor I Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity.
(12 Dec 1998)
receptors, insulin-like-growth-factor II Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity.
(12 Dec 1998)
receptors, macrophage colony-stimulating factor Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • pattern glass
    Àå½Ä ¹«´Ì°¡ µç À¯¸® Á¦Ç°
  • pier glass
    â »çÀÌ º®¿¡ °Å´Â ü°æ
  • pier glass
    ü°æ
  • plate glass
    µÎ²¨¿î ÆÇÀ¯¸®
  • prism glass
    ÇÁ¸®Áò ½Ö¾È°æÀÇ ±¼Àý ¹Ý»ç ·»Áî
  • rain glass
    û¿ì°è
  • reading glass
    È®´ë°æ;ÀÜ ±ÛÀÚ¿ë ·»Áî;µ¶¼­¿ë ¾È°æ
  • reducing glass
    Ãà¼Ò·»Áî
  • ruby glass
    »¡°£ À¯¸®
  • safety glass
    ¾ÈÀüÀ¯¸®
  • sheet glass
    ÆÇÀ¯¸®
  • spun glass
    À¯¸® ¼¶À¯
  • volcanic glass
    Èæ¿ä¼®
  • watch glass
    (È­ÇÐ ½ÇÇè¿ëÀÇ)½Ã°è Á¢½Ã
  • water glass
    ¹°¾È°æ;¹°ÄÅ;¹°À¯¸®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á